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Abstract 
Background: Understanding Cambodia’s anti-malarial and diagnostic landscape in 2015 is critical for informing and 
monitoring strategies and policies as Cambodia moves forward with national efforts to eliminate malaria. The aim of 
this paper is to present timely and key findings on the public and private sector anti-malarial and diagnostic land-
scape in Cambodia. This evidence can serve as a baseline benchmark for guiding implementation of national strate-
gies as well as other regional initiatives to address malaria elimination activities.
Methods: From August 17th to October 1st, 2015, a cross sectional, nationally-representative malaria outlet survey 
was conducted in Cambodia. A census of all public and private outlets with potential to distribute malaria testing 
and/or treatment was conducted among 180 communes. An audit was completed for all anti-malarials, malaria rapid 
diagnostic tests (RDT) and microscopy.
Results: A total of 26,664 outlets were screened, and 1303 outlets were eligible and interviewed. Among all screened 
outlets in the public sector, 75.9% of public health facilities and 67.7% of community health workers stocked both 
malaria diagnostic testing and a first-line artemisinin-based combination therapy (ACT). Among anti-malarial-stocking 
private sector outlets, 64.7% had malaria blood testing available, and 70.9% were stocking a first-line ACT. Market 
share data illustrate that most of the anti-malarials were sold or distributed through the private sector (58.4%), includ-
ing itinerant drug vendors (23.4%). First-line ACT accounted for the majority of the market share across the public and 
private sectors (90.3%). Among private sector outlets stocking any anti-malarial, the proportion of outlets with a first-
line ACT or RDT was higher among outlets that had reportedly received one or more forms of ‘support’ (e.g. reportedly 
received training in the previous year on malaria diagnosis [RDT and/or microscopy] and/or the national treatment 
guidelines for malaria) compared to outlets that did not report receiving any support (ACT: 82.1 and 60.6%, respec-
tively; RDT: 78.2 and 64.0%, respectively).
Conclusion: The results point to high availability and distribution of first-line ACT and widespread availability of 
malaria diagnosis, especially in the public sector. This suggests that there is a strong foundation for achieving elimina-
tion goals in Cambodia. However, key gaps in terms of availability of malaria commodities for case management must 
be addressed, particularly in the private sector where most people seek treatment. Continued engagement with the 
private sector will be important to ensure accelerated progress towards malaria elimination.
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Background
Over the past decade, malaria interventions have made 
substantial progress in Cambodia, demonstrated by rapid 
declines in the malaria burden since the early 2000s, with 
reported cases decreasing by approximately 50% between 
2004 and 2014 [1]. However, of Cambodia’s 25 provinces, 
21 are still considered to be endemic, and an estimated 
48% of the population live in high transmission areas 
[2]. Furthermore, there has been a resurgence of malaria 
cases between 2014 and 2015, from 44,748 to 56,371, and 
resistance to artemisinin-based combination therapy 
(ACT) continues to threaten progress towards national 
malaria strategies [3]. This situation is all the more press-
ing given the country’s recent commitment to eliminate 
malaria by 2020, as coverage of appropriate case manage-
ment in the context of malaria elimination strategies will 
be critical to achieving this goal [1].
In 2016, Cambodia’s National Centre for Parasitol-
ogy, Entomology and Malaria Control (CNM) released 
the Malaria Elimination Action Framework, 2016–
2020, (MEAF) outlining the country’s strategies and 
plans to achieve elimination of Plasmodium falciparum 
and multi-drug resistant malaria by 2020 [1]. Several 
key objectives are described in the MEAF, including 
100% parasitological diagnosis for all suspected cases 
and effective, efficacious treatment of all confirmed 
uncomplicated malaria cases using first-line ACT: dihy-
droartemisinin-piperaquine (DHA PPQ) or artesunate–
mefloquine (ASMQ) fixed-dose combination (FDC). For 
P. falciparum infections or mixed infections that include 
P. falciparum, the MEAF stipulates use of a single low-
dose of primaquine. For P. vivax infections, a standard 
dose of primaquine for up to 14 days is indicated in order 
to prevent relapse. The MEAF stipulates that glucose-
6-phosphate dehydrogenase (G6PD) testing should be 
conducted prior to administering primaquine treatment 
for Plasmodium vivax cases.
The MEAF also outlines several key strategies to ensure 
readiness of public and private facilities to adhere to the 
national treatment guidelines for malaria [1]. Malaria 
treatment or referral services will be available at all public 
health facilities, licensed private sector providers, trained 
village malaria workers (VMW), mobile malaria work-
ers, and military medical services. In the public sector, 
the VMW programme, which provides malaria diagno-
sis and treatment among remote communities through 
a community-based health workforce, will be scaled 
up. The number of villages with at least one VMW will 
almost double, from 2539 currently to 4528 over the 
course of the next 5 years. In addition, these community-
based providers will be allowed to administer low dose 
primaquine for P. falciparum to reduce malaria trans-
mission and for radical cure of P. vivax. The VMW will 
also receive training on malaria, case management, coun-
seling, and health education.
In the private sector, where most patients in Cambo-
dia seek treatment [4], the strategy outlines the scale-up 
of the existing public–private mix (PPM) programme 
by mapping all existing providers and registering new 
providers. Refresher courses on early malaria diagno-
sis, treatment, referral, and reporting will be conducted 
every 2 years for PPM programme providers. The strat-
egy also specifies that providers that do not qualify for 
the PPM programme will not be allowed to provide or 
sell anti-malarials or diagnostics. However, efforts will 
also be made to identify and select unlicensed private 
providers that can be targeted for licensing so that they 
can be registered under the PPM programme. Several ini-
tiatives will be implemented to enforce the regulation of 
private sector service providers through the Department 
of Drug and Food (DEF) and the Anti-Economic Crime 
Police. Finally, the strategy also stipulates that there will 
be increased efforts to ban the import and sale of anti-
malarial drugs that are not in the national malaria treat-
ment guidelines [1]. This will be implemented by keeping 
the DDF updated on the anti-malarial drugs that are not 
included in the national malaria treatment guidelines.
These current national strategies outlined in the MEAF 
build on the country’s earlier efforts to promote expan-
sion of the public sector and increased regulation of the 
private sector [5, 6]. In the public sector, the VMW pro-
gramme has been a key strategy for increasing access to 
malaria commodities among remote rural populations. 
By 2014, a decade after it was piloted in 300 villages, the 
VMW programme covered over 1600 villages and 130 
mobile communities across 17 malaria endemic prov-
inces [1]. Private sector engagement has been in place 
since 2002, through national distribution of subsidized 
anti-malarials and rapid diagnostic testing (RDT) for pri-
vate sector providers across the country [6]. In 2008, oral 
artemisinin monotherapy was banned, with several hard-
line strategies in place to enforce the policy [7]. Increased 
regulation of the private sector commenced around this 
time, to reduce the role of unauthorized private sector 
providers, including drug stores and general retailers, in 
anti-malarial distribution, while continuing to support 
distribution by registered private for-profit health facili-
ties and pharmacies. In 2011, the CNM and the Ministry 
of Health (MoH) established the aforementioned PPM 
programme to further engage the private sector and pro-
vided subsidized commodities, training, and supervi-
sion. The PPM programme was subsequently scaled up in 
2014, with nearly 1200 licensed private providers enrolled 
across 34 operational districts (ODs) out of a total of 45 
malaria endemic ODs [1]. Indeed, efforts to date by the 
CNM and other implementing partners have been highly 
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successful in strengthening and shaping Cambodia’s anti-
malarial and malaria diagnostic landscape. Supply-side 
evidence from 2013 has shown an increase in the wide-
spread distribution of first-line ACT, successful removal 
of oral artemisinin monotherapy, a decrease in the num-
ber of unregulated outlets stocking anti-malarials, and an 
increase in public sector anti-malarial market share and 
composition, namely through the VMW programme [5].
Evidence on the role and performance of the public 
and private sectors will provide a baseline benchmark 
for guiding implementation of national strategies. The 
ACTwatch project, implemented since 2008 across a 
number of countries by Population Services International 
(PSI), provides timely, relevant, and high quality anti-
malarial market evidence to inform and monitor national 
and global policy, strategy, and funding decisions for 
improving malaria case management [8, 9]. In 2015, an 
ACTwatch survey was implemented in Cambodia. The 
evidence generated from this project provides an oppor-
tunity to present contemporary market intelligence data 
on Cambodia’s anti-malarial and diagnostic landscape as 
a means to inform and monitor strategies and policies as 
the country moves forward with elimination activities. 
The evidence from this survey can also help to frame the 
anti-malarial and diagnostic market in the context of the 
MEAF strategies, as well as other regional and country-
specific initiatives to accelerate progress towards elimina-
tion of malaria. The objectives of this paper are twofold: 
(1) to describe contemporary public and private sector 
readiness (availability of malaria commodities) and per-
formance (market share) for malaria case management; 
and (2) to compare private sector readiness and provider 
knowledge between outlets that reportedly received 
supportive interventions (e.g. access to malaria commod-
ities, or training) with private outlets that did not receive 
these interventions.
Methods
Design and sampling
The study population was defined as all outlets with the 
‘potential’ to sell or distribute anti-malarial medicines 
and/or provide malaria blood testing. The methodology 
of ACTwatch adopts a more inclusive, rather than exclu-
sive, way of determining outlet types for the study, by 
including a broad list of outlet types that may or may not 
sell or distribute anti-malarial medicines and/or provide 
malaria blood testing. While some outlets are expected 
to have anti-malarials, other outlets, such as general 
retailers, may be theorized to not stock these medicines. 
Such outlets are, however, included in the sample as a 
means to investigate this theory and to determine if these 
outlets do indeed contribute to malaria case management 
in a given country. Outlet types that are included in the 
sample are determined according to each specific coun-
try context. The outlet types that were included in the 
Cambodia survey are described in Table  1. Outlets that 
did not serve the general public (e.g. military facilities) 
were excluded from the outlet survey, but military and 
police facilities that also served the general public were 
included.
In 2014, the World Health Organization (WHO) used 
available evidence about artemisinin resistance to define 
a 3-tier stratification system for targeting action to 
address drug resistance [10]. This tier system replaced 
the previous zone stratification used in Cambodia [11]. 
Areas designated as Tier 1 were prioritized for immediate 
Table 1 Outlet types and definitions
Sector and facility type Definition
Public sector
 Public health facilities Referral hospitals, health centers, former district hospitals, health posts, NGO/mission/faith-based hospitals, NGO/
mission/faith-based clinics, and NGO/mission/faith-based diagnostic laboratories
 Community health workers Community-based volunteers, either Village Malaria Workers, Mobile Malaria Workers, or Plantation Malaria Workers, 
who are equipped with anti-malarial treatment and malaria blood testing
Private sector
 Private for-profit health facilities Private hospitals, clinics, polyclinics, cabinets, health care rooms, and private diagnostic laboratories and would be 
expected to have been registered in country
 Pharmacies Regulated by a national regulatory authority and staffed by pharmacists or qualified health practitioners. These 
include pharmacies, clinical pharmacies, depot A, and depot B. These may or may not be licensed by a national 
regulatory authority
 Drug stores Drug stalls in rural markets or shops that primarily sell medicines. These outlets are not guaranteed to be staffed by 
qualified health dispensers or practitioners and are not typically licensed by a national regulatory authority
 General retailers Grocery stores and village shops and are not licensed by a national regulatory authority
 Itinerant drug vendors Mobile providers found primarily in rural areas, typically working within a radius of their home. They are not regis-
tered with any national regulatory authority. Some itinerant drug vendors operate with both a fixed location and 
a mobile service, while others operate solely through a mobile service.
Page 5 of 16ACTwatch Group  et al. Malar J  (2017) 16:171 
multifaceted response to contain or eliminate resistance. 
Areas designated as Tier 2 were prioritized for intensified 
malaria control to reduce transmission and/or limit the 
risk of emergence or spread of resistant parasites. Tier 3 
areas had no evidence of artemisinin resistance and lim-
ited contact with Tier 1 areas. Malaria control in these 
areas focused on vector control, increasing coverage with 
confirmatory testing and treatment with quality-assured 
ACT [12]. The Cambodia outlet survey was stratified to 
deliver estimates for domains according to this tier strati-
fication system, with the first research domain designated 
as tier 1 provinces and the second research domain des-
ignated as tier 2 provinces.
From a list of all communes in each research domain, 
the required number of units was selected with probabil-
ity proportional to size (PPS). Selection of units with PPS 
was completed based on population estimates obtained 
from a 2010 Ministry of Planning projection based on 
findings from the 2008 national census. The sampling 
frames for each tier excluded communes that were 
located in non-malaria-endemic areas according to infor-
mation provided by the CNM.
Within each commune, a census of all outlets with the 
potential to sell or distribute anti-malarials and/or pro-
vide malaria blood testing was conducted. Outlets were 
eligible for a provider interview and malaria product 
audit if they met at least one of three study criteria: (1) 
one or more anti-malarials reportedly in stock on the day 
of the survey; (2) one or more anti-malarials reportedly 
in stock within the three months preceding the survey; 
and/or (3) malaria RDT in stock or malaria microscopy 
available on the day of the survey.
Sample size
Sample size was determined to estimate with preci-
sion (±10% points) two key indicators among public 
and private outlets: (1) proportion of outlets with first-
line anti-malarial treatments available, among outlets 
with anti-malarial(s) in stock on the day of the survey; 
and (2) proportion of outlets with malaria blood testing 
(RDT or microscopy) available, among outlets with anti-
malarial(s) in stock on the day of the survey or within the 
past 3 months. Estimates from the 2013 ACTwatch outlet 
survey were used to complete these calculations. A sam-
ple size of 80 Tier 1 and 80 Tier 2 communes was antici-
pated to yield the minimum required numbers of outlets.
Data collection
Standard procedures used by the ACTwatch project 
to implement surveys have been described elsewhere 
[27]. Interviewers, supervisors, and quality controllers 
received training that included an orientation to the study 
and questionnaire, classroom training on completing 
anti-malarial and RDT audits, and a field exercise. Fol-
lowing training, data collection was implemented from 
August 17th to October 1st, 2015. The outlet survey was 
conducted using handheld devices with an Android oper-
ating system and electronic forms created using DroidDB 
(SYWARE, Inc., Cambridge, MA, USA). The question-
naire was translated from English to Khmer, and trans-
lated back into English to resolve any discrepancies prior 
to the survey implementation.
A series of screening questions were administered at 
all outlets to determine eligibility for the survey. Outlets 
where anti-malarial medicines were reportedly sold and/
or malaria blood testing was reportedly available were 
invited to participate in the survey. Following informed 
consent procedures, an audit of all available anti-malarial 
medicines and RDT was conducted. In addition to the 
product audit, a series of questions was administered to 
the senior-most provider regarding malaria case manage-
ment knowledge and practices as well as provider train-
ing and qualifications and reporting on malaria caseload 
data. Up to three visits were made to all outlets to com-
plete the screening process, audit, and provider interview 
as needed.
Data analysis
Electronic data were imported to a master dataset using 
Microsoft Access (Microsoft Corporation, Redmond, 
Washington, USA), and records were triangulated with 
questionnaires, field supervisor tracking records, and 
daily activity logs completed by interviewers. All data 
cleaning and analysis was completed using Stata 12.1 
(StataCorp, College Station, TX, USA). Sampling weights 
were applied to account for variations in probability of 
selection, and standard error estimation accounted for 
clustering at the commune level.
Indicators were produced according to ACTwatch 
standards that have been implemented across time and 
country studies and which have been described in detail 
elsewhere [8, 9]. Availability of any anti-malarial was 
calculated with a denominator of all screened outlets. 
In the public sector, the availability of specific types of 
anti-malarials was calculated using the denominator of 
all screened outlets, given that anti-malarials should be 
available at all public health facilities and community 
health workers (CHW) designated as VMW. Availability 
of specific anti-malarial categories in the private sector 
was calculated using a denominator of private sector out-
lets stocking any anti-malarial.
The volumes of each anti-malarial that were report-
edly distributed in the week prior to the survey, accord-
ing to provider reports, were standardized into adult 
equivalent treatment doses (AETD) to allow for com-
parisons between medicines, based on WHO treatment 
Page 6 of 16ACTwatch Group  et al. Malar J  (2017) 16:171 
guidelines for the amount of active ingredient required 
to treat an adult weighing 60 kg [13]. These standardized 
AETD volumes were then used to calculate market share 
for each anti-malarial category. Audited medicines that 
were missing information required to calculate AETD 
(strength or amount distributed) were excluded from this 
indicator.
Private sector outlet support status (the presence or 
absence of support) was calculated according to mul-
tiple provider self-reported variables. An outlet was 
considered as having received any support if the pro-
vider reported one or more of the following: (1) outlet 
received subsidized anti-malarials and/or malaria RDT; 
(2) at least one provider at the outlet received training on 
the national treatment guidelines for malaria or malaria 
diagnosis within the previous year; (3) outlet received a 
supervisory/regulatory visit within the previous year; 
and/or (4) outlet reports malaria caseload data to the 
government or a non-governmental organization. Sup-
port status was very likely to be correlated with outlet 
type, given that governmental and non-governmental 
organizations target only registered private health facili-
ties and pharmacies for support and do not typically sup-
port unauthorized drug stores, general retail outlets, or 
itinerant drug vendors. Availability and provider knowl-
edge indicators for supported and non-supported out-
lets were therefore adjusted for outlet type using logistic 
regression to produce adjusted predicted probabilities. 
Anti-malarial availability indicators were calculated 
among outlets with any anti-malarial in stock on the day 
of the survey. Malaria blood testing availability and pro-
vider knowledge of first-line treatment indicators were 
calculated among outlets with any anti-malarial in stock 
on the day of the survey or within the three months prior 
to the survey.
Results
Sample description
A total of 26,664 outlets were screened to assess eligibility 
for the outlet survey, and only 51 outlets refused screen-
ing or survey participation. Of the outlets screened, 604 
(2.3%) were in the public sector, and 26,060 (97.7%) were 
in the private sector. A total of 1303 outlets were eligi-
ble and interviewed, and only five outlets met eligibility 
criteria but did not complete the interview. Of the eligi-
ble outlets, 557 (42.7%) were in the public sector, and 746 
(57.3%) were in the private sector.
Of the 1303 outlets interviewed, 858 (65.8%) were 
stocking at least one anti-malarial on the day of the sur-
vey, 1112 (85.3%) were stocking at least one anti-malarial 
either on the day of the survey or within the previous 
three months, and 191 (14.7%) were stocking a malaria 
diagnostic test (either RDT or microscopy) but did not 
stock anti-malarial medicines on the day of the survey or 
within the previous three months.
In total, 164 outlets reported distributing an anti-
malarial during the week prior to the survey, and 427 
outlets reported providing or distributing a malaria diag-
nostic test in the week prior to the survey. Table 2 shows 
a detailed breakdown of the screening, eligibility, and 
interview results across outlet types and sectors. Provider 
characteristics are included in Additional file 1.
Availability in the public sector
Table  3 shows a detailed breakdown of malaria blood 
testing availability, first-line anti-malarial availability, and 
readiness for malaria case management across screened 
public sector outlets. Availability of malaria diagnostics 
was relatively high in the public sector, with 85.9% of 
all public sector outlets stocking either malaria RDT or 
microscopy, and this was highest among CHW (87.2%). 
Availability of malaria RDT was higher than microscopy, 
with 85.8% of public sector outlets stocking malaria RDT 
and only 7.2% reporting availability of malaria micros-
copy. Malaria microscopy was available in only 27.8% of 
public health facilities.
Availability of first-line ACT in the public sector was 
slightly lower than diagnostic availability, with just under 
three-fourths of all public sector outlets (74.7%) stock-
ing any first-line ACT on the day of the survey. Among 
these outlets, 100% of the first-line ACT audited was 
DHA PPQ, as no outlets were stocking ASMQ FDC. Pri-
maquine was not available in any public sector outlets.
Three-fourths of public health facilities (75.9%) had 
both malaria diagnostic testing and a first-line ACT. 
Malaria case management readiness was lower among 
CHW, with only 67.7% of CHW stocking both malaria 
testing and first-line treatment.
Availability in the private sector
Table 4 shows a detailed breakdown of availability of any 
anti-malarial among all private sector outlets, followed 
by availability of malaria blood testing and anti-malarials 
among anti-malarial-stocking private sector outlets.
Approximately one-third of screened private for-profit 
health facilities (31.0%), one-fifth of pharmacies (20.5%), 
and 15.1% of itinerant drug vendors were stocking any 
anti-malarial on the day of the survey. Of 23,840 general 
retailers screened, only 0.2% were found to be stocking 
any anti-malarial.
Among anti-malarial-stocking private sector outlets, 
nearly two-thirds had malaria blood testing available 
(64.7%); 63.8% were stocking a malaria RDT, while 8.7% 
had malaria microscopy available. Availability of malaria 
blood testing was highest in private for-profit health 
facilities (83.0%) and pharmacies (70.1%). Over half of 
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itinerant drug vendors were stocking a diagnostic test 
(60.4%).
Among those private sector outlets stocking any anti-
malarial, 70.9% were stocking a first-line ACT, all of 
which was DHA PPQ rather than ASMQ FDC. Private 
for-profit health facilities and pharmacies had the highest 
availability of a first-line ACT (90.0 and 85.6%, respec-
tively). Availability of a first-line ACT was also moder-
ately high among anti-malarial-stocking itinerant drug 
vendors (62.8%). Fewer than half of anti-malarial-stock-
ing drug stores (47.9%) and only 2.8% of anti-malarial-
stocking general retailers had a first-line ACT available. 
Chloroquine was most commonly available among drug 
stores (20.5%), general retailers (67.1%), and itinerant 
drug vendors (30.7%). Only one package of oral AMT 
was found, and this product was audited at a general 
retail outlet.
Market share
Figure  1 shows a detailed breakdown of the anti-malar-
ial market share across sectors, outlet types, and anti-
malarial type. Most of the anti-malarials were sold or 
distributed through the private sector (58.4%). Across the 
private sector, most of the anti-malarial market share was 
composed of private for-profit health facilities (26.7%) 
and itinerant drug vendors (23.4%).
In terms of the types of anti-malarials being sold or 
distributed, DHA PPQ contributed to the majority of 
the market share in both the public and private sectors 
(90.3% of the national market share). The private sector 
anti-malarial market share was also composed of chlo-
roquine (4.9%), which was primarily distributed through 
private for-profit health facilities, general retailers, and 
itinerant drug vendors.
Figure  2 shows a detailed breakdown of the diagnos-
tic market share across sectors, outlet types, and diag-
nostic test type. The majority of the diagnostic market 
share was composed of the private sector (57.6%), with 
most diagnostic tests provided through private for-profit 
health facilities (37.9%), itinerant drug vendors (9.1%), 
and pharmacies (8.6%). Most diagnostic testing was per-
formed using RDT rather than microscopy.
Private sector support
Table  5 shows a detailed breakdown of support report-
edly received across private sector outlet types. Nearly 
half of all interviewed outlets (44.4%) reported having 
received any type of support. Nearly two-thirds of pri-
vate for-profit health facilities (60.2%) and nearly three-
fourths of pharmacies (71.7%) reported having received 
any type of support, while one in four itinerant drug ven-
dors (25.5%) reported receiving any type of support.
Among outlets that reported receiving support, the 
most common types of support reportedly received 
were access to subsidized RDT (63.0%), training in the 
past year on malaria diagnosis or the national treatment 
guidelines for malaria (59.1%), and access to subsidized 
anti-malarials (57.5%). Only 21.4% reported receiving a 
supervisory or regulatory visit within the past year, and 
36.9% reported keeping and reporting malaria caseload 
Table 3 Availability of malaria commodities and readiness for case management in the public sector, among all screened 
outlets
Public health facility Community health workers All public sector
N = 173 N = 430 N = 603
%  (95% CI) % (95% CI) % (95% CI)
Diagnostics
 Any malaria blood testing 82.3 (74.9, 87.8) 87.2 (82.7, 90.6) 85.9 (82.1, 89.0)
 Malaria microscopy 27.8  (21.0, 35.8) 0.3 (0.1, 1.8) 7.2 (5.3, 9.7)
 RDT 81.7 (74.3, 87.4) 87.2 (82.7, 90.6) 85.8 (81.9, 88.9)
Anti-malarials
 Any first-line ACT (DHA PPQ and/or ASMQ FDC) 76.5 (67.8, 83.5) 74.1 (66.2, 80.7) 74.7 (68.3, 80.1)
 DHA PPQ 76.5 (67.8, 83.5) 74.1 (66.2, 80.7) 74.7 (68.3, 80.1)
 ASMQ FDC 0.0 (–) 0.0 (–) 0.0 (–)
 Primaquine 0.0 (–) 0.0 (–) 0.0 (–)
 Other non-artemisinin therapy 8.9 (4.9, 15.5) 0.0 (–) 2.2 (1.3, 3.9)
 IV/IM artesunate 0.0 (–) n/a 0.0 (–)
Readiness
 Availability of first-line ACT and malaria blood testing 75.9 (67.1, 82.9) 67.7 (60.2, 74.3) 69.7 (63.6, 75.1)
 Availability of first-line ACT, blood testing not available 0.7 (0.2, 2.4) 6.4 (4.1, 9.9) 5.0 (3.2, 7.6)
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data to either the government or a non-governmental 
organization.
Figure  3 shows several key indicators showing anti-
malarial and diagnostic market availability, and provider 
knowledge, according to outlet support status (the pres-
ence or absence of private sector support), while control-
ling for outlet type. Among private sector outlets stocking 
any anti-malarial, the proportion of outlets with a first-
line ACT was higher among outlets that had reportedly 
received any type of support or engagement (hereinafter 
referred to as ‘supported’ outlets) compared to outlets 
that did not report receiving any support (82.1 and 60.6%, 
respectively). Similar results were observed for availabil-
ity of malaria blood testing, where 78.2% of supported 
outlets had a malaria blood test available compared to 
64.0% of unsupported outlets. With regards to provider 
knowledge, 80.2% of providers in supported outlets cor-
rectly stated the first-line treatment for uncomplicated 
malaria (either DHA PPQ or ASMQ FDC) compared to 
just 47.0% of providers in unsupported outlets. Finally, 
supported outlets were less likely to be stocking an anti-
malarial not indicated in the national treatment guide-
lines for malaria compared to unsupported outlets (14.0% 
compared to 43.0%, respectively).
Figure  4 shows median prices for malaria RDT and 
DHA PPQ according to outlet support. Outlets that 
reported having received any type of support reported 
a median consumer price of $0.75 for a malaria RDT 
Table 4 Availability of malaria commodities in the private sector
Private for-profit 
health facility
Pharmacy Drug store General retailer Itinerant drug vendor All private sector
% (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
Among all screened 
outlets, availability of
N = 668 N = 290 N = 338 N = 23,840 N = 924 N = 26,060
 Any anti-malarial 31.0 (26.1, 36.3) 20.5 (14.8, 27.6) 6.6 (4.2, 10.1) 0.2 (0.1, 0.4) 15.1 (11.4, 19.8) 1.8 (1.5, 2.1)
Among anti-malarial-
stocking outlets or 
outlets stocking 
anti-malarials in the 
past 3 months, avail-
ability of
N = 237 N = 74 N = 34 N = 39 N = 186 N = 570
 Diagnostics
  Any malaria blood 
testing
83.0 (76.8, 87.8) 70.1 (58.2, 79.7) 60.9 (40.8, 77.9) 0.0 (–) 60.4 (50.6, 69.4) 64.7 (58.5, 70.3)
  Malaria microscopy 15.6 (10.9, 22.0) 4.8 (1.6, 13.1) 4.0 (0.6, 21.7) 0.0 (–) 5.6 (3.2, 9.8) 8.7 (6.4, 11.9)
  RDT 81.3 (74.8, 86.5) 70.1 (58.2, 79.7) 60.9 (40.8, 77.9) 0.0 (–) 59.8 (50.0, 68.9) 63.8 (57.6, 69.6)
Among anti-malarial 
stocking outlets, avail-
ability of
N = 186 N = 45 N = 22 N = 29 N = 109 N = 391
Anti-malarials
  Any first-line ACT 90.0 (82.5, 94.5) 85.6 (74.3, 92.4) 47.9 (27.8, 68.6) 2.8 (0.5, 15.6) 62.8 (51.7, 72.7) 70.9 (63.1, 77.6)
  DHA PPQ 90.0 (82.5, 94.5) 85.6 (74.3, 92.4) 47.9 (27.8, 68.6) 2.8 (0.5, 15.6) 62.8 (51.7, 72.7) 70.9 (63.1, 77.6)
  ASMQ FDC 0.0 (–) 0.0 (–) 0.0 (–) 0.0 (–) 0.0 (–) 0.0 (–)
  Primaquine 0.0 (–) 0.0 (–) 0.0 (–) 0.0 (–) 0.0 (–) 0.0 (–)
  Chloroquine 4.6 (2.0, 10.3) 7.7 (2.9, 19.1) 20.5 (9.7, 38.1) 67.1 (27.6, 91.6) 30.7 (20.1, 43.7) 19.7 (14.1, 26.9)
  Other non-arte-
misinin therapy
1.3 (0.3, 5.4) 0.0 (–) 6.8 (1.9, 21.4) 0.0 (–) 1.8 (0.6, 5.2) 1.5 (0.7, 3.3)
  Oral AMT 0.0 (–) 0.0 (–) 0.0 (–) 2.3 (0.4, 12.7) 0.0 (–) 0.2 (0.0, 1.2)
  IV/IM artesunate 0.0 (–) 0.0 (–) 0.0 (–) 0.0 (–) 0.7 (0.1, 4.0) 0.2 (0.0, 1.3)
  Availability of 
first-line ACT and 
malaria blood 
testing
80.4 (72.6, 86.3) 67.1 (52.5, 79.0) 23.6 (10.0, 46.1) 0.0 (–) 50.8 (40.2, 61.3) 59.4 (51.9, 66.6)
  Availability of first-
line ACT, blood 
testing not avail-
able
9.6 (6.1, 15.0) 18.5 (10.5, 30.5) 24.3 (9.4, 49.9) 2.8 (0.5, 15.6) 12.0 (7.0, 19.9) 11.5 (8.4, 15.4)
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compared to a median price of $1.49 in unsupported out-
lets. Similarly, the median price of one AETD of DHA 
PPQ in supported outlets was $1.24 compared to $2.49 in 
unsupported outlets.
Discussion
The 2015 outlet survey findings provide contemporary 
evidence on the availability and market share of malaria 
commodities. Several positive outlet survey findings 
regarding the readiness and performance of the public 
and private sectors are observed: first-line ACT avail-
ability and distribution was widespread, and malaria 
diagnosis was commonplace—particularly in the public 
sector. However, the data also highlight key gaps across 
both sectors that must be addressed and which are dis-
cussed further in this section.
Public sector readiness to test and treat for malaria
Readiness to appropriately manage malaria cases, meas-
ured through availability of malaria blood testing and 
a first-line ACT, was observed at only approximately 
two-thirds of public health facilities, indicating that 
around one in three public health facilities were lack-
ing the capacity to both diagnose and appropriately 
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Table 5 Percent of  private sector outlets who reportedly received government or non-governmental support, 
and among outlets who received a support strategy, type of support received
Private for-profit 
health facility
Pharmacy Drug store General retailer Itinerant drug vendor All private sector
% (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
N = 326 N = 99 N = 46 N = 39 N = 235 N = 745
Received any type of 
support
60.2 (53.6, 66.4) 71.7 (61.7, 80.0) 45.5 (29.7, 62.2) 3.2 (0.7, 13.8) 25.5 (18.8, 33.6) 44.4 (39.0, 49.9)
Among outlets with 
support
N = 196 N = 69 N = 19 N = 1 N = 64 N = 349
 Report access to subsi-
dized anti-malarials
58.3 (49.2, 66.9) 69.4 (58.7, 78.5) 26.8 (13.3, 46.6) 0.0 (–) 55.7 (44.4, 66.5) 57.5 (51.1, 63.7)
 Report access to subsi-
dized RDT
63.5 (54.0, 72.1) 69.1 (58.9, 77.7) 60.2 (36.4, 80.0) 0.0 (–) 58.6 (45.5, 70.7) 63.0 (55.9, 69.6)
 Report received train-
ing in the past year 
on malaria diagnosis 
(RDT and/or micros-
copy) and/or the 
National treatment 
guidelines for malaria
65.3 (57.1, 72.7) 66.0 (53.2, 76.8) 36.1 (18.0, 59.2) 100.0 (–) 42.6 (31.5, 54.4) 59.1 (53.9, 64.2)
 Report receiving a 
supervisory or regu-
latory visit within the 
past year
27.6 (21.7, 34.3) 17.8 (8.9, 32.6) 20.7 (5.5, 54.0) 0.0 (–) 8.6 (3.9, 18.0) 21.4 (16.7, 27.0)
 Report keeping and 
reporting malaria 
caseload data to 
government or 
non-government 
organization
50.3 (40.0, 60.6) 22.2 (11.8, 37.9) 18.0 (4.0, 53.4) 0.0 (–) 21.1 (11.7, 35.0) 36.9 (27.8, 47.1)
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treat uncomplicated malaria. According to Cambodia’s 
national treatment guidelines for malaria, and in order 
to achieve the universal coverage strategy described in 
the MEAF, all of the public sector outlet types must be 
equipped to test for and treat uncomplicated malaria. 
Moving forward, it will be critical to maintain a constant 
supply of malaria commodities. At the time of this sur-
vey, the CNM was developing the Logistic Management 
Information System (LMIS) to measure quantification, 
long-lasting insecticide-treated net (LLIN) demand, 
forecasting, and stock, with the aim of providing more 
regular reports and thus reducing the frequency of stock 
outs in the public sector [14]. The LMIS is expected to 
ideally move the country towards universal coverage by 
ensuring a constant supply of malaria commodities at all 
public sector outlets. Indeed, findings from other coun-
tries have supported this prediction, demonstrating that 
investments to strengthen management information sys-
tems can lend a more streamlined, demand-driven, and 
accountable procurement and supply chain system [15].
The role of the private sector
The majority of private sector outlets screened were 
not in the business of stocking malaria commodities, 
with fewer than one in three private for-profit health 
facilities and one in five pharmacies stocking an anti-
malarial. This reflects an overall decline in anti-malarial 
availability among these private sector outlets in recent 
years [5]. In 2015, malaria case management services in 
the private sector were concentrated among private for-
profit health facilities and pharmacies, which are the 
only private sector outlet types authorized to distrib-
ute anti-malarial medicines [1]. The concentration of 
malaria commodities among authorized outlet types may 
reflect increased regulation of the private sector and/or 
may also be a result of a decline in provider incentives to 
stock anti-malarials, given declining burden and perhaps 
less consumer demand for malaria treatment. However, 
the relatively low availability of malaria commodities in 
the private sector indicates that a febrile patient seeking 
care in the private sector may have to approach multiple 
facilities to find one with malaria testing and treatment. 
This points to the importance of a referral system, such 
as the Private Sector SMS Referral System piloted in 2012 
by the CNM and partners [16], as well as a need to scale 
up health services at the community level.
While most private sector outlets were not in the 
business of malaria case management, results nonethe-
less show that the private sector was responsible for the 
majority of anti-malarial distribution and malaria testing 
provision. This finding is consistent with other research 
in Cambodia and neighboring countries such as Lao 
PDR and Myanmar [17, 18]. Market share data also illus-
trate that, while a large portion of the private sector case 
management was channeled through private for-profit 
health facilities and pharmacies, there was also a signifi-
cant contribution from itinerant drug vendors—an illicit 
and unregulated outlet type in Cambodia. Although itin-
erant drug vendors are not a formal or regulated outlet 
type, provider demographic results show that approxi-
mately one in five itinerant drug vendors reported hav-
ing completed university or college, and nearly two in 
three itinerant drug vendors reported having a health 
qualification, mostly as a nurse or nursing officer. This 
suggests that these providers could be considered assets 
in improving appropriate malaria case management 
coverage, if they can be appropriately regulated and 
supervised.
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The MEAF has outlined plans to target certain unli-
censed providers and encourage them to obtain a licence 
in order to join the PPM programme, and it also describes 
goals to enforce existing laws that would prohibit opera-
tion of itinerant drug vendors. However, there may be 
some benefit from further exploration into whether itin-
erant drug vendors could be effectively licensed and reg-
ulated under the PPM programme. Several studies have 
documented success with the VMW programme [5, 19], 
which has increased access to appropriate malaria case 
management in many rural areas of Cambodia utilizing 
people with overall less education and fewer baseline 
health qualifications compared to itinerant drug ven-
dors (Additional file  1). In sub-Saharan Africa, several 
malaria-endemic countries have documented improve-
ments in provider knowledge and performance after 
implementation of strategies such as training and capac-
ity-building, demand generation, quality assurance, and 
creating an enabling environment, all of which targeted 
the informal private sector, including itinerant drug ven-
dors [20]. Furthermore, the WHO has recommended the 
engagement of itinerant drug vendors, where appropri-
ate, as a method of improving home-based management 
of malaria [21, 22], and analyses by the U.S. Agency for 
International Development (USAID) have also concluded 
that policies through which national programmes engage 
with private providers—both formal and informal—can 
be beneficial to improving provision of care for malaria 
and other important health issues in developing coun-
tries [23]. Extending permission to test for and treat 
malaria to trained and supervised itinerant drug vendors 
may be an important strategy in Cambodia to accelerate 
universal coverage of confirmatory testing and appropri-
ate malaria treatment and to continue expanding cover-
age to remote, rural populations.
Private sector readiness and performance
Where anti-malarials were available in the private sector, 
the majority of anti-malarial stocking outlets had a first-
line ACT available. However, nearly one in three private 
sector outlets were not stocking a first-line ACT and 
were primarily stocking chloroquine, which is no longer 
indicated for use in the national treatment guidelines 
for malaria. While the majority of anti-malarial-stock-
ing private sector outlets had malaria diagnostic testing 
available, approximately one in three did not have test-
ing available. These gaps in private sector readiness are a 
threat to appropriate management of suspected malaria 
cases, as they demonstrate a potential for presumptive 
anti-malarial treatment and/or treatment with medicines 
that are not indicated in the national treatment guide-
lines for malaria.
Most anti-malarials distributed by the private sector 
were DHA PPQ, a first-line ACT. However, chloroquine 
and artemisinin–piperaquine were also distributed in the 
private sector, indicating that some private sector provid-
ers were not in full alignment with the national treatment 
guidelines for malaria. Indeed, availability data show that 
all private sector outlet types were found to be stock-
ing chloroquine, with the highest availability observed 
among general retailers. While availability and market 
share of a first-line treatment were high among private 
for-profit health facilities and pharmacies, chloroquine 
stubbornly persists and most notably among itiner-
ant drug vendors, pointing to the need to completely 
remove this anti-malarial from the market. One strategy 
by which to achieve this goal would be to ban the import 
and sale of this anti-malarial, especially given evidence 
that a similar ban on oral artemisinin monotherapy in 
2008 was found to be a successful measure to remove this 
anti-malarial from the market [5]. This is also addressed 
in the MEAF strategy, which stipulates that there will 
be increased efforts to ban the import and sale of anti-
malarial drugs not in national treatment guidelines for 
malaria.
Private sector support
Results from this study showed that access to any sup-
portive intervention—including subsidized anti-malar-
ials or RDT, training, supervisory or regulatory visits, 
or reporting caseload data—was associated with higher 
availability of a first-line ACT, higher availability of 
malaria testing, higher provider knowledge of first-line 
treatment guidelines for malaria, and lower availability of 
an anti-malarial not in the national treatment guidelines 
for malaria. In addition, the study showed that private 
sector outlets with access to any supportive interven-
tion priced their malaria commodities lower than outlets 
that did not have access to any supportive intervention, 
meaning more affordable access to malaria testing and 
treatment for consumers.
These results suggest that strategies such as subsidies, 
training, and supervision can improve private sector 
readiness and performance, as has been demonstrated in 
other contexts [24]. However, this study was not designed 
to evaluate specific types of private sector support, nor 
was it able to compare the performance of PPM outlets 
with non-PPM outlets. There is further need to examine 
the outcomes associated with the various aspects of the 
PPM programme to identify where there may be a need 
to strengthen specific components. The extent to which 
the measures of access to supportive interventions, as 
outlined in this paper, can be used to inform specific 
strategies relating to the PPM programme is limited.
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Results from this study reflect positively on the work 
that has been done to-date in Cambodia to engage the 
private sector. However, there is a need to increase cov-
erage of private sector support and, in doing so, more 
evidence about the performance of current strategies is 
needed in order to facilitate efficient and effective pro-
gress in the private sector. As intended under the PPM 
programme, current strategies appear to be reaching pri-
vate health facilities and pharmacies to a much greater 
extent than itinerant drug vendors. As noted above, 
extending private sector support to itinerant drug ven-
dors may be an important strategy for improving overall 
private sector readiness and performance. In addition, 
investigation into the merits of other types of private sec-
tor strategies, such as integration of RDT financial incen-
tives and information, education, and counseling, may 
be useful interventions as evidenced among the infor-
mal private sector in neighboring Myanmar [25]. Finally, 
future research that specifically addresses the PPM 
programme may be merited in order to better under-
stand how this strategy has affected anti-malarial and 
diagnostic market performance to date and in order to 
more specifically inform policy decisions relating to this 
programme.
Gaps in availability of ASMQ FDC and primaquine
In its continuing effort to keep one step ahead of drug 
resistance, Cambodia’s national treatment guidelines for 
malaria changed in 2014 in response to emerging resist-
ance to DHA PPQ, such that ASMQ FDC is now rec-
ommended in geographic areas with DHQ PPQ failure. 
As of June 2015, failure rates of DHA PPQ have reached 
over 60% in certain areas of the country, pointing to the 
immediate need to ensure access to ASMQ FDC [1]. 
During data collection for this survey, which took place 
in August and September of 2015, ASMQ FDC was not 
found. The absence of this anti-malarial in the market 
may be due in part to a variety of challenges with manu-
facturing and procurement. Cambodia has faced pro-
curement challenges in the past, most notably after the 
switch in malaria treatment guidelines to DHA PPQ 
in 2010, when a lack of suitable manufacturers led to a 
significant delay and subsequent stock out of first-line 
anti-malarials in both the public and private sectors 
[5]. In light of the constantly changing epidemiology of 
malaria in Cambodia and the Greater Mekong Subregion 
(GMS) as a whole, it is important that the country is able 
to respond quickly to changing treatment recommenda-
tions and thus avoid lags in the stocking of appropriate 
treatments. One option to consider are parallel procure-
ment systems whereby two or more types of anti-malar-
ial are stocked in-country to guarantee the availability 
of an appropriate anti-malarial depending on the drug 
resistance, while accepting that drug wastage will be an 
inevitable reality in the drive toward elimination [5]. 
Other considerations may include investment into a 
centralized procurement system, with trained person-
nel, storage capacity, infrastructure and IT enablement 
in order to forecast stock and supply, and distribution of 
sufficient quantities of anti-malarials with minimal delays 
[26]. In addition, any identification of treatment failure 
should signal the need to start immediately forecasting 
sufficient stock for new first-line treatments.
The MEAF and the national treatment guidelines for 
malaria stipulate the use of primaquine to prevent P. fal-
ciparum transmission and P. vivax relapse, indicating 
that it should be provided along with a first-line ACT for 
both types of malaria. This study found that primaquine 
was universally unavailable at the time of the survey. 
This may reflect hesitancy to operationalize the use of 
primaquine without a feasible way to test first for G6PD 
deficiency [27]. However, WHO recommendations and 
supporting publications demonstrate that a low dose 
of primaquine can be safely administered regardless of 
G6PD status [28–30]. As Cambodia scales up access to 
primaquine, approaches used in neighboring countries 
such as Myanmar, Thailand, and Vietnam may be use-
ful to consider, as governments have limited the use of 
primaquine to facilities that are equipped to either test 
and/or monitor for signs of G6PD deficiency. However, it 
should be noted that outlet survey evidence from Myan-
mar and Thailand illustrates that primaquine availability 
in these facilities was generally lower compared to other 
first-line treatments for uncomplicated malaria [31]. This 
suggests that there may be issues in maintaining constant 
supply or may demonstrate concerns by the governments 
that facilities are not adequately equipped to either test 
and/or monitor for signs of G6PD deficiency. Build-
ing on evidence from other countries that have histori-
cally included and implemented the use of primaquine 
in their treatment policy will be helpful to facilitate full 
implementation of the national treatment guidelines for 
malaria in Cambodia.
Limitations
Despite its many strengths, the ACTwatch outlet sur-
vey has several limitations which have been described in 
detail elsewhere [8, 32]. Notably, the survey had a cross 
sectional design, which limits the conclusions that can be 
drawn about causality as it relates to access to supportive 
interventions and performance indicators in the private 
sector. It is also acknowledged that, due to increased reg-
ulation of the private sector, especially as it relates to the 
stocking of oral artemisinin monotherapy, providers may 
have a disincentive to accurately report certain informa-
tion, such as the stocking of artemisinin monotherapy or 
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the stocking of any malaria commodities in outlets which 
were unlicensed.
Conclusions
As Cambodia steps into an era of malaria elimination, 
evidence on the availability and distribution of first-line 
treatment for malaria and malaria diagnostic testing in 
the public and private sectors is critical. Evidence from 
the last ACTwatch outlet survey implemented in 2015 
illustrates that there is a strong foundation for meeting 
national malaria elimination goals: first-line ACT avail-
ability and distribution was widespread, and malaria 
diagnosis was commonplace—particularly in the pub-
lic sector. This evidence can serve as a benchmark for 
guiding the implementation of strategies outlined in the 
MEAF as well as other regional initiatives to address 
elimination activities. The private sector remains respon-
sible for the majority of malaria testing and treatment 
in Cambodia, indicating that strategies to effectively 
support the private sector are critical to continued pro-
gress. Identifying other regulatory strategies or support-
ive interventions to address anti-malarial availability and 
distribution by unauthorized itinerant drug vendors is 
needed.
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VMW: village malaria worker; WHO: World Health Organization.
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